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Abstract 
The impact of dietary interventions such as specific types of diet or nutritional 
supplements in rheumatoid arthritis (RA) has been subject to increased attention in recent 
years. The recognition of the unmet need to better understand the effects of specific 
dietary interventions on disease outcomes in RA, along with the growing patient interest 
on lifestyle interventions beyond pharmacotherapy, have informed the undertaking of this 
narrative literature review.  The benefits of the Mediterranean Diet (MD) have been 
shown in various studies, although only a limited number of trials focus specifically on 
RA.  Based on the studies reviewed, the MD may provide benefits in reducing pain and 
swollen and tender joints in RA patients. There is more and better evidence that n-3 
polyunsaturated fat (PUFA) supplementation has the potential to reduce inflammation 
and provide clinical benefit, possibly slowing progression to pharmacotherapy.  Yet, 
many of these studies to date are limited in their methodology; this being partly a 
reflection of the complexity of the research questions being addressed. Consequently, the 
conclusions that can be robustly drawn from their results are restricted. With a focus on 
clinical trials on the MD and fish oil supplementation, this review critically appraises the 
evidence, discussing the findings of studies in the wider context of impact on RA 
outcomes, methodological challenges and practical points to consider as part of the 
routine care of RA patients. 
 
Keywords: Mediterranean diet, fish oils, fatty acids, rheumatoid arthritis, patient-
reported outcomes, DMARDs 
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Abbreviations 
5-HETE 5-Hydroxyeicosatetraenoic acid 
ALA alpha-linolenic acid 
ACR20 American College of Rheumatology 20% improvement criteria 
AID Anti-inflammatory Diet 
AA arachidonic acid 
CO corn oil 
CRP C-reactive protein 
COX-2 cycloxygenase-2 
DAS28 Disease Activity Score-28 
DMARD disease-modifying antirheumatic drug 
DHA docosahexaenoic acid 
DPA docosapentaenoic acid 
EPA eicosapentaenoic acid 
ESR erythrocyte sedimentation rate 
EULAR European League Against Rheumatism 
EVOO extra-virgin olive oil 
FO fish oil 
GLA gamma-linolenic acid 
GS grip strength 
HDFO high dose fish oil 
IL interleukin 
IU International Units 
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IV intravenous 
JAK janus kinase 
LTB4 Leukotriene B4 
LTB5 Leukotriene B5 
LA linoleic acid 
LDFO low dose fish oil 
MD Mediterranean Diet 
NSAID non-steroidal anti-inflammatory drugs 
OO olive oil 
PUFA polyunsaturated fatty acids 
RA Rheumatoid Arthritis 
RF Rheumatoid factor 
SFA saturated fat 
SOFI Signals of Functional Impairment 
SJC swollen joint count 
TJC tender joint count 
HAQ Health Assessment Questionnaire 
TNF-a Tumor Necrosis Factor alpha 
UP urinary pentosidine 
VO Vegetable oil 
VAS visual analogue pain 
VAS Visual Analogue Scale 
WD Western Diet () 
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1. Introduction 
Rheumatoid arthritis (RA) is a chronic, immune-driven inflammatory disease that 
continues to cause modest global disability [1].  Poorly controlled RA is associated with 
multiple clinical symptoms including fatigue, severe pain and functional disability, 
ultimately also ‘end-stage’ joint damage necessitating surgical intervention [2].  An 
increasing comorbidity burden, most importantly of cardiovascular disease has also been 
reported in RA, even at the early stages of disease with a negative impact on the 
achievement of treat-to-target goals [3].  Immunosuppression remains the cornerstone of 
treatment for RA and this is traditionally achieved through the use of conventional 
synthetic disease modifying anti rheumatic drugs (DMARDs), steroids and more targeted 
therapies including biologic DMARDs (e.g. Tumor Necrosis Factor (TNF)-α inhibitors) 
or small molecules (e.g. janus kinase [JAK] inhibitors).  These treatments have made 
remission a possible treatment target in RA.  Yet, there remains a substantial proportion 
of people who continue to suffer ongoing symptoms of disease, despite the use of 
effective pharmacotherapy.   
It is thus perhaps not surprising that in an attempt to relieve their symptoms, 
patients often seek (‘unorthodox’) dietary ‘therapies’ as an adjuvant or even a 
replacement to their ‘traditional’ treatments; this is despite the reported outcomes being 
highly variable and the attribution of a proportion of their improvement to placebo effects 
[4].  Common dietary plans tried/used and reported in RA, include among many 
vegetarian or vegan diets, the Mediterranean diet (MD) or even various periods of 
fasting, while dietary supplements, especially n-3 polyunsaturated fatty acids (PUFA) or 
fish oils are commonly used.  Whether these dietary interventions make a difference and 
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the extent of their effects in terms of the inflammatory burden and clinical symptoms, 
remains in part open to speculation and represents an unmet need.  Having robust 
scientific evidence on which to base specific advice and recommendations as part of the 
routine clinical care of patients with RA is important, especially as it is an often-
encountered question posed by patients (e.g. ‘What can I eat / What supplements can I 
take to improve my symptoms/ Are there foods I should eat/not eat?’), albeit one that 
tends to be poorly addressed.   
The increasing recognition of this unmet need to understand and appreciate the 
impact of dietary interventions on disease course in RA was well-reflected in the recent 
17
th
 Mediterranean Congress of RA and musculoskeletal diseases dedicated to nutrition 
and the environment [5].  It also stimulated this narrative review of literature presented 
here, which was based on a search for relevant papers on Medline and Embase via the 
OVID SP platform upto July 2017 using the following terms: Rheumatoid arthritis or 
arthritis, rheumatoid or inflammatory arthritis and Mediterranean diet or omega-3 
supplements or fish oil supplements or fish oil infusions, restricting to clinical trials.  This 
work was informed by increased patient interest and focused on dietary interventions 
such as the MD and n-3 PUFA fish oil supplementation that may be practically applied 
by patients and which could ultimately contribute to the development of Dietary 
Guidelines for people with RA.   
 
 
2. The Mediterranean Diet  
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2.1 Key effects of the Mediterranean Diet on inflammation 
The MD is characterized by an abundance of plant foods such as unrefined cereals, fruit, 
vegetables, legumes and extra-virgin olive oil (EVOO), a moderate consumption of 
poultry, dairy products and eggs and a low consumption of sweets and red meat [6].  As a 
rich source of antioxidants and anti-inflammatory nutrients, it seems to have a potential to 
modulate inflammatory pathways in RA [7;8] although the evidence from clinical trials is 
currently limited [9].  Central to the suppression of RA disease activity is the abundance 
of EVOO in the MD which contains not only oleic acid, an n-9 monounsaturated fatty 
acid (18:1, n-9), but also the phenolic compounds oleuropein, ligstroside and oleocanthal, 
and phenolic alcohols, such as hydroxytyrosol and tyrosol with potent anti-oxidant 
properties [8].  Ingestion of dietary EVOO [10] and EVOO-polyphenol extract [11] by 
collagen-induced RA mice has been shown to reduce joint edema and cartilage 
destruction; effects associated with reduced expression of inflammatory cytokines such as 
interleukin (IL)-1β, IL-6 and transduction signaling molecules [7;8].  Additionally, 
phenolic compounds both from olive oil but also from red wine such as resveratrol, 
inhibit cycloxygenase-2 (COX-2) protein expression and prostanoid and 
metalloproteinase production, important in angiogenesis, the key pathogenenic process in 
inflammatory chronic joint diseases [7].  Further to its antioxidant and anti-inflammatory 
properties, the MD is also rich in dietary fiber with beneficial effects on gut microbiota, 
promoting saccharolitic microbiota and favoring short-chain fatty acid production [12].  
Gut microbiota regulate the T cell phenotype and T cell-mediated immunity and seem to 
have a role in RA development while gut dysbiosis contributes to the occurrence or 
development of a range of rheumatic diseases [13;14]. 
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2.2 Clinical trial data 
The effects of MD in RA patients have only been assessed in two clinical trials. McKellar 
et al [15] conducted a 6 month pilot study in 130 female patients with RA living in areas 
of social deprivation in Glasgow.  The intervention group attended a 6-week cookery 
course with emphasis on a MD-type diet, while the control group received information on 
health eating only.  At 6 months, the intervention resulted in a significant benefit in 
global assessment, pain score and early morning stiffness (EMS).  Other RA outcomes 
assessed i.e. tender joint count (TJC), swollen joint count (SJC), Disease Activity Score 
28 (DAS28), Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) or IL-6 
did not differ between groups. Although the authors concluded that the MD has modest 
benefits across a range of areas, the study had a number of limitations, in that random 
allocation to intervention or control was not feasible, statistical analysis was based on 
comparing the two groups at different time points instead of the changes from baseline, 
and the study included only females living in socially deprived areas and thus cannot be 
generalized to other populations.  Additionally, most of the changes were in subjective 
rather than objective measures of disease and since the intervention group received such 
intense training, the possibility of placebo effect and the risk of bias remains high.    
In another MD intervention study, Sköldstam et al [16] investigated the efficacy 
of a MD versus an ordinary Western diet (WD) for suppression of disease activity in 51 
patients with RA in Sweden.  A 3-month randomized controlled trial (RCT) was 
conducted where RA patients were randomly allocated to either a Cretan MD or a control 
WD.  During the first 3 weeks, the diet group was served an MD from the hospital 
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canteen and a dietitian provided six lessons about MD food and cooking.  Participants 
were supplied with monounsaturated oils and spreads, frozen vegetables and tea.  The 
control group were served ordinary hospital food for the first 3 weeks and asked to return 
to their usual diets for the rest of the study period.  Compliance was ascertained by a 
questionnaire and by dietary history interviews and validated by biological markers of 
food intake.  At the end of the 12-week intervention, the MD showed improvements in 
RA outcomes such as DAS and HAQ scores, SJC, TJC, patients’ global visual analogue 
scale (VAS), Pain VAS, CRP and thrombocyte count.  There were also improvements in 
vitality and mental health, but no significant changes were seen in EMS, erythrocyte 
sedimentation rate (ESR), grip ability test (GAT) score or signals of functional 
impairment (SOFI) score.  No improvements were seen in the control group.  Although 
the study showed that adjusting to the MD can result in a reduction in inflammatory 
activity and an increase in physical function, the findings may not be generalized since it 
included mostly women, adjusted the MD to suit the Swedish subjects and had a short 
duration.   
A key challenge and an important source of bias in studies that involve dietary 
manipulations, is the impossibility to ‘blind’ subjects to the diet being followed.  On the 
other hand, studies involving supplementation, like the ones discussed below, are not 
generally limited by the issue of blinding.  
 
3 Fish oil supplements  
 
3.1 Key effects of n-3 PUFA on inflammation 
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In contrast the traditional diets such as the MD, the WD is usually characterized by 
deficiency in consumption of n-3 PUFA, especially the fish oils eicosapentanoic acid 
(EPA; 20:5 n-3), docosahexaenoic acid (DHA; 22:6, n-3), and increased consumption of 
n-6 PUFA such as linoleic acid (LA; 18:2 n-6) or arachidonic acid (AA; 20:4; n-6), 
derived mostly from vegetable oils such as sunflower and corn oil and animal sources.  In 
fact, the vast roles of n-3 PUFAs as proinflammatory mediators has led to the recent 
recommendation of the Omega-3 Index (red blood cell EPA+DHA) to assess sufficiency 
of intake [17]. Dietary essential fatty acids are precursors of the inflammatory mediator 
prostaglandins (PGs) and leucotrienes (LTs) with n-6 and n-3 fatty acids having potent 
inflammatory and anti-inflammatory properties respectively. While the most potent 
inflammatory PGs originate from the n-6 AA, EPA competitively inhibits the production 
of PGs and LTs from AA by competing for the same enzymatic pathway while it also 
acts as the precursor of the less inflammatory series-3 PGs and series-5 LTs [18].  Dietary 
supplementation with n-3 PUFA has a number of anti-inflammatory actions as recently 
reviewed [19], with examples including reduction of the proinflammatory activities of 
AA, increase in the production of endocannabinoids having EPA or DHA in their 
structure and thus anti-inflammatory properties, reduction in the production of 
inflammatory cytokines such as IL-1β, IL-6 and TNF-α, reduction in the expression of 
adhesion molecules on immune cells and on endothelium, reduction in T-cell 
proliferation and the production of IL-2, as well as restoration of the homeostasis of 
tissues after inflammation through metabolites acting as specialized pro-resolving 
mediators.   
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 In an attempt to study the anti-inflammatory actions of n-3 PUFA in RA 
outcomes, a range of studies using n-3 PUFA supplements provided mostly orally and in 
some studies intravenously (IV), varying in methodology, dosage, duration and outcomes 
examined, have been conducted as discussed in Sections 3.2-3.8. 
   
3.2 Effects of low n-3 PUFA doses on RA outcomes 
Studies using relatively low n-3 PUFA doses include Remans et al [20] where 55 RA 
patients were randomized to a liquid nutritional supplement providing 1.4 g EPA, 0.211 g 
DHA, 0.4 g DPA, 0.16 g ALA, 0.5 g GLA and 0.44 g LA and micronutrients, consumed 
for 4 months, or a placebo drink.  Patients in the intervention group reported a 
significantly decreased consumption of NSAID at 3 and 6 months while physician’s 
global assessment improved at 3 months.  On the other hand, control patients reported an 
increased global arthritic activity at 6 months.  However, other parameters such as 
ACR20 response criteria, SJC, TJC, CRP and ESR concentrations and HAQ score did not 
change.  The study thus did not show any significant clinical benefit of daily nutrient 
supplementation with EPA, GLA and micronutrients. It did show some potential effect of 
fish oils on decreasing need for NSAID usage, however even here the findings were 
limited.  
Sköldstram et al [21] conducted a 6-month double-blind RCT in 43 RA patients.  
The intervention consisted of 10 capsules/day containing 1 g fish oil, 18% EPA and 12% 
DHA while the control group received capsules made of maize, olive and peppermint oil.  
At the end of the intervention, both groups had a significant reduction in joint tenderness 
and increase in grip strength (GS) and platelet count while the placebo group had an 
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increase the ESR and a decline in global arthritic activity.  Although use of NSAID 
significantly decreased in the intervention compared to the control group, patients’ pain 
assessment using VAS, functional capacity and duration of EMS showed no change 
throughout the treatment in either of the groups.  Thus, taken together studies using low 
doses show that FO supplementation may cause only a slight anti-inflammatory effect 
and have limited potential for lowering the NSAID intake in patients with RA. 
 
3.3 Effects of higher n-3 PUFA doses on RA outcomes 
Higher doses of n-3 PUFA supplements were used in other studies such as 
Cleland et al [22] who conducted a double-blind RCT in 46 patients with RA.  The 
intervention consisted of 18 g fish oil/day providing 3.2g EPA and 2 g DHA with the 
control group receiving the same amount of olive oil.  After three months of treatment 
there were significant improvements in TJC and GS in the fish oil treated group. The 
olive oil group also experienced significant improvements in EMS and GS. However 
there was no significant change in either group in SJC, the ARA functional class, or 
global assessment by patient and physician.  Although the findings of this study suggest 
that higher n-3 PUFA supplementation could reduce some of the symptoms of RA, the 
study is limited in that there was a high drop-out rate and the inappropriate use of olive 
oil in the control group, which has itself anti-inflammatory properties [23].   
Nielsen et al [24] also used a higher dose of n-3 at 3.6 g/day in a multicenter 
double blind RCT with the participation of 51 RA patients. The control group received 
six capsules/day each containing the equivalent amounts of a combination of fats 
typically present in a Danish diet.  Unlike most other studies, compliance was assessed by 
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the increase of EPA in leucocyte fatty acids and shown to be significant in the 
intervention group. Joint tenderness improved in both groups but statistical significance 
was only achieved in the intervention group. No statistically significant findings were 
seen in the VAS pain score, GS, DAS or SJC.  It is unclear why control patients also 
benefited from the study but this may be related to the fatty acids provided in the placebo 
arm of the study which themselves may have (unrecognized) anti-inflammatory actions.   
Rajaei et al [25] in a better controlled 12-week double blind RCT of n-3 PUFA 
supplementation of 1.8 and 2.1 g EPA and DHA daily, evaluated the effects on disease 
activity and remission in 60 DMARD-treated RA patients.  Placebo drugs consisted of 
starch thus overcoming the issue of possible confounding by use of other dietary fatty 
acids. Weight changes and reduction of analgesic drug consumption were also assessed.   
Significant improvements were seen in the n-3 PUFA treated group in EMS, severity of 
pain, physician’s assessment, number of SJC, TJC and physical function.  It was thus 
shown that n-3 PUFA supplementation may reduce the need for concomitant analgesic 
consumption without weight changes.   
 
3.4 Comparison of n-3 PUFA doses on RA outcomes 
Investigators have also tried to examine the effects of different amounts of n-3 
supplements.  To that effect, Geusens et al [26] randomly assigned RA patients to one of 
three regimens for 12 months: 2.6 g/day n-3, or 1.3 g/day n-3 plus 3 g olive oil, or 6 g 
olive oil used as placebo.  A balanced diet was also advised.  There were significant 
improvements in the patient's global evaluation and in the physician's assessment of pain 
only in those taking 2.6 g/day n-3 PUFA.  Additionally, the proportions of patients who 
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improved and of those who were able to reduce their concomitant anti-rheumatic 
medications were significantly greater with the higher n-3 PUFA dose.  There were no 
significant changes in the ESR, Rheumatoid Factor (RF), JSC or EMS.  Although the 
study concluded that a higher dose of fish oil supplementation has significant clinical 
benefits to RA patients, and may ultimately reduce need for medication, it had a high 
drop-out rate of 30% and compliance was assessed only by capsule counting.   
 Kremer et al [27] also assessed the effects of two different doses of fish oil and 
one dosage of olive oil on clinical evaluations and immunologic variables in RA patients.  
Patients were randomized to either a low dose of n-3 PUFAs (27 mg/kg EPA and 18 
mg/kg DHA; n=20), a high dose n-3 PUFAs (54 mg/kg EPA and 36 mg/kg DHA; n=17) 
or 6.8 g of oleic acid capsules (n=12).  Over the study period, there were improvements 
in several RA clinical manifestations in both the low-dose and high-dose fish oil groups 
but also some in the olive oil group.  Particularly, there were reductions in SJC, TJC and 
GS in both fish oil groups and improvement in patient and physician evaluation of pain 
only in the high-dose fish oil group.  Interestingly patient evaluation of global arthritis 
activity improved only in the olive oil-supplemented group. There were also 
improvements in the physician’s evaluation of global arthritis activity in the low fish oil 
and olive oil groups.  Lastly, significant improvements in physician evaluation of global 
arthritis activity were seen in the high-dose fish oil group only, with a carryover 
improvement noted at 30 weeks when all patients were taking olive oil supplements.  
Neutrophil leukotriene B4 production decreased from baseline in both fish oil groups 
while macrophage IL-1 production decreased in all 3 groups.  Thus although overall, 
ingestion of n-3 fatty acids led to beneficial effects on RA clinical parameters which were 
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sustained and more commonly observed after 18-24 weeks of treatment, the study is 
limited in that the olive oil group experienced a high number of withdrawals as a result of 
the increased disease activity in this group.  Furthermore, as in previous studies e.g. 
[22;26], olive oil was again inappropriately used as placebo.   
 
3.5 Combined dietary interventions and n-3 PUFA supplementation on RA disease 
outcomes 
Some investigators attempted to combine dietary supplementation with changes in 
diet.  For example, Kremer et al [28], in a highly-cited study published in the Lancet, 
assessed the effects of manipulation of dietary fatty acids, by combining dietary changes 
and supplementation, in a 12-week, double-blind RCT. The experimental diet was high in 
PUFA and low in saturated fat (SFA), with a daily supplement of 1.8 g of EPA (n=17) 
while the control diet had a lower PUFA:SFA ratio combined with a placebo supplement 
(n=20).  At 12-weeks, both groups showed a significant decrease in the TJC, but the 
mean decrease was greater in the experimental than the control group.  There were no 
differences between patients’ and physicians’ assessments of pain and overall condition 
in either group.  At a follow-up evaluation 1-2 months after stopping the intervention, the 
status of the patients in the experimental group had deteriorated substantially while some 
improvements in the TJC and EMS were noted in the control group patients.  Thus, 
overall the findings suggest that a higher PUFA intake might have some beneficial effects 
but these were not substantial.   
Adam et al [29] conducted a double-blind crossover study aiming to examine fish 
oil (FO) supplementation in combination with a low AA diet in 62 individuals with RA.  
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One group was observed for 8 months on a WD and the other on an anti-inflammatory 
diet (AID) providing an AA intake of less than 90 mg/day. Patients in both groups were 
allocated to receive placebo (corn oil) or fish oil capsules (30 mg/kg body weight) for 3 
months in with a 2-month washout period between treatments.  In the AID group there 
was a reduction in SWJ and TJC during placebo treatment while fish oil led to a 
significant reduction in SJC and TJC only in the AID group.  The patients' and 
physicians’ global assessments of disease activity and the patients’ assessments of pain 
improved in both groups but this was higher in the AID group.  It was also possible to 
reduce the dose of NSAID in the AID group during FO.  The study did not report 
differences in EMS or GS. Overall, the findings of this study suggest that there is 
synergism in a diet low in AA and high in FO, which in turn shows that EPA:AA ratio is 
crucial for consideration in a clinical advice.  
A double blind cross-over RCT study by Dawczynki et al [30] measured the 
effect of fish oil-supplemented dairy products on the inflammation and the 
immunological and oxidative stress biomarkers, disease activity and serum lipids in 39 
RA patients. Both groups received verum products or placebo for 3 months consecutively 
with a 2-month washout period. The patients received approximately 40g fat (from 200 g 
of 3.8% fat yoghurt and 30g of 50% fat cheese and 20-30 g butter), daily. The milk fat 
was partially replaced with fish, rapeseed and Dracocephalum ibericum oil, which are all 
high in EPA, DHA and ALA. The combination of n-3 PUFA came up to a daily intake of 
2.4 g.  Commercial dairy products with comparable, but non-n-3 fatty acid fat contents 
were used in the placebo group.  Compliance to the intervention was measured through 
daily dietary diary entries. Acute-phase reactants and activity parameters such as CRP, 
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ESR, SJC, TJC, EMS and DAS28 score did not change significantly over the study 
period.  There were also no effects on biomarkers of oxidative stress but long-term 
consumption of dairy products (2 x 12 weeks) diminished the excretion of 
hydroxypyridinium crosslinks, and favored the diastolic blood pressure leading the 
authors to comment that it acts against the cartilage and bone destruction in RA.  Thus 
overall, there is limited evidence of a synergism between a low AA acid diet and n-3 
supplementation used at medium dosage on RA outcomes. 
 
3.6 n-3 PUFA supplements and possible effects on medication use 
Studies have also investigated whether dietary supplementation with n-3 PUFAs 
would allow the discontinuation of medication or the slower progression to therapeutic 
interventions.  To that effect, Kremer et al [31] investigated in double blind RCT whether 
n-3 supplementation would allow nonsteroidal anti-inflammatory drug (NSAID) 
discontinuation.  66 RA patients entered the study while taking diclofenac and were 
randomized to either 130 mg/kg/day of n-3 PUFA or 9 capsules corn oil per day.  Placebo 
diclofenac was substituted at week 18 or 22 while fish oil supplements were continued 
for another 8 weeks.  At 26 or 30 weeks, fish oil supplements were substituted by corn 
oil.  In the group taking fish oil, there were significant decreases from baseline in the 
TJC, duration of EMS, physician’s and patient’s evaluation of global arthritis activity and 
physician’s evaluation of pain.  No clinical parameters improved in the corn oil group.  
When diclofenac was replaced by placebo, the fish oil group experienced significant 
worsening in patient’s global evaluation, GS, physician’s evaluation of pain and TJC. 
During this period, patients consuming corn oil showed significant worsening in both the 
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physician’s and the patient’s evaluation of global arthritis activity and in the patient’s 
evaluation of pain, but not in the TJC.  Interestingly, the decrease in the TJC remained 
significant 8 weeks after discontinuing diclofenac in the fish oil group.  Although there 
was a significant decrease in IL-1β between baseline and weeks 18/22 in the fish oil 
group, the intervention did not result in inhibition of other assessed cytokines (IL-2, IL-6, 
IL-8 or TNF-α).  In summary, the study showed some beneficial effects of fish oil 
supplementation in RA clinical parameters, but none of the improvements in the patients 
receiving fish oil achieved significance at the time of the maximum duration of 
diclofenac therapy compared with patients receiving corn oil.  Whether this is due to 
beneficial immunologic effects of the placebo corn oil used, remains unknown.  
Moreover, the magnitude of the improvement observed with a very high fish oil dose 
reaching 9 g/day in a 70 kg person, was similar to that reported with lower doses (3-6 
g/day) [27;28], leading the authors to conclude that further investigations with this high 
dose should not be recommended.  Additionally, the study had a very high dropout rate; 
this being 26% dropout by week 22 and 56% by the end of the study.    
 Galarraga et al [32] conducted a 9-month dual-centre double-blind RCT to 
examine whether 2.2 g of n-3 EPA (taken as 10 g of cod liver oil) could help reduce daily 
NSAID requirement in 97 RA patients.  At 12 weeks, patients were instructed to 
gradually reduce or if possible stop their NSAID intake.  A higher percentage in the cod 
liver oil group compared to the control group were able to reduce their daily NSAID 
requirement by >30% at 9 months (39 vs 10%; p=0.002, intention-to-treat analysis).  As 
per study’s objective, this was indeed achieved without worsening the patients’ condition 
since no differences were observed in clinical parameters or RA disease activity.  Indeed 
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there was a modest but statistically significant improvement in the mean pain VAS from 
baseline in the cod liver oil group compared to the control group.  Additionally, there 
were no differences in side-effects between the groups.  The study thus provides evidence 
that n-3 PUFA can be used as NSAID-sparing agents, it is limited however in that there 
was a 40% dropout due to adverse events, patient’s wishes or lack of efficacy.  
Lastly, Proudman et al [33] in an eloquently designed double-blind RCT, 
examined the effects of fish oil supplements on use of DMARD using a treatment 
algorithm responsive to disease activity according to predefined rules, thus allowing the 
extent of DMARD use to be an outcome measure.  139 patients with recent onset RA and 
who were DMARD-naïve were randomized 2:1 to fish oil at high dose (5.5 g/day EPA + 
DHA) or low dose (0.4 g/day EPA + DHA) for 1 year.  In the high dose group, failure of 
triple DMARD therapy was lower even when adjusted for smoking history, shared 
epitope and baseline anti-cyclic citrullinated peptide.  The rate of first American College 
of Rheumatology (ARC) remission was significantly greater in the fish oil group but no 
differences between groups were noted in methotrexate dose, DAS28, the modified 
Health Assessment Questionnaire (mHAQ) scores or adverse events.  The study showed 
that fish oil supplementation can provide benefits additional to those achieved by 
combination ‘treat-to-target’ DMARDs with similar methotrexate use, thus at least 
delaying progression to biological therapy.  In a further analysis [34], it was shown that 
plasma phospholipid EPA (but not DHA) was related to time of remission, thus providing 
evidence that biomarkers of n-3 status can predict clinical outcomes in RA patients. 
 
3.7 Intravenous n-3 PUFA administration  
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Of interest are studies that report on IV administration of n-3 FAs, suggesting 
good tolerability of the treatment and potentially greater efficiency than oral 
administration [35;36].  However, these studies are limited by their study design 
including the length of follow up, small numbers and high attrition rates thus decreasing 
the power of studies to detect ‘true’ effects of n-3 FAs. Furthermore, the study definitions 
of ‘disease control’ and ‘efficiency’ of the tested interventions can vary, with some 
studies referring to improvement in these parameters when subjective measures alone e.g. 
SJC and TJC, improve.  For example, Bahadori et al [35]in a double-blind RCT of 0.2g 
of fish oil emulsion/kg (active) or 0.9% (placebo) IV infusion for 14 consecutive days, 
followed by 20 weeks of 0.05g of fish oil/kg (active) or paraffin wax (placebo) ingested 
orally as capsules, report on significantly lower SJC and TJC in n-3 FA group compared 
with placebo during and at the end of oral treatment; it should, however, be noted that 
this was the case for around 50% of the patients in total, completing the study.  
Interestingly, placebo treatment also led to a considerable reduction of SJCs and TJCs, 
which the authors concluded ‘may be due to the placebo effect as well as the intensified 
physician’s attention and care to both groups’.  In the study by Leeb et al [36] although 
attrition rates were lower, IV administration of n 3-PUFA was only given for a week.   In 
this study 2mL/kg (equal to 0.1-0.2 g fish oil/kg) IV fish oil emulsion was used for 7 
consecutive days plus background therapy.   
It is worth highlighting that none of the two studies demonstrated an improvement 
in objective measures of disease such as laboratory markers.  Therefore, whereas these 
studies provide a rationale for potentiating serum omega-3 FA levels through use of 
infusion therapy of omega 3 FA, their study design, type and timing of outcome measures 
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studied raise crucial questions around the appropriateness of the studies in answering 
their respective research question.  In addition, the cost and practicalities of IV 
administration of such therapies necessitate further cost-effectiveness studies on this 
topic, to justify their more widespread use.  
 
3.8 Meta-analyses on n-3 PUFA supplementation 
Since effects seen at low n-3 PUFA doses are generally not of clinical significance, using 
the right dosage is of paramount importance if any effects are to be seen.  In particular, a 
meta-analysis of RCTs on fish oil supplements in RA reported a benefit for patient-
assessed pain, EMS, number of painful and/or tender joints and NSAIDs consumption 
[37].  A further meta-analysis of 10 RCTs evaluating the effects of n-3 PUFAs at doses 
≥2.7 g/day for a minimum of 3 months [38] on clinical outcomes in RA showed that n-3 
PUFAs reduced NSAID consumption but TJC, SJC, EMS, physical function, showed a 
trend to improve but did not reach statistical significance.  Since the conduction of these 
meta-analyses, further evidence as presented here has shown that n-3 supplementation at 
2.2-4.0g/day could help reduce daily NSAID requirement and concomitant analgesic 
consumption [32], while 5.5 g/day of n-3 for 12 months can delay progression to 
biological therapy in DMARD-naïve patients [33].   
 
4. What can we conclude from MD/Fish oil supplementation trials? 
Tables 1 and 2 summarize the participant characteristics, interventions used and main 
findings of the studies presented.  Based on the studies reviewed, the MD may provide 
benefits in reducing pain, SJC, TJC in RA patients. There is more and better evidence 
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that n-3 PUFA supplementation has the potential to reduce inflammation and provide 
clinical benefit in RA patients, although in many cases, only subjective, nevertheless, the 
importance of dosage, duration, potential side-effects and practicalities of intake need to 
be addressed. It should be noted that many of the presented studies have a number of 
methodological flaws.  Several are based on only a small sample size and/or have a high 
dropout rate while being biased by reporting outcomes on the patients retained in the 
study rather than using an ‘intention-to-treat’ analysis.  Additionally, the duration of the 
clinical trials, with some exceptions, is usually short to study important outcomes of 
disease making it challenging to disentangle the biological ‘plausibility’ of the potentially 
expected findings from administration of n-3 FAs and true (non-placebo) clinical effects.   
This becomes even more difficult in light of the fact that many studies used inappropriate 
‘placebo’ treatments such as olive oil or corn oil capsules which as discussed have 
themselves, anti-inflammatory actions.   Additionally, a number of studies reported on 
greater effects on the more subjective elements of disease such as SJC/TJC with less 
evidence on more objective features of active RA such as laboratory markers or 
radiographic progression.  Whereas this may alone point towards the evidence being 
‘weak’ in this aspect, the mere impact on those outcomes that are of greater relevance to 
the patients’ themselves, including pain, EMS, fatigue, makes it all worthwhile.  On the 
other hand, there is conflicting evidence from studies on the impact of n-3 FA on the 
acute phase response e.g. CRP concentration.   
Nevertheless, despite the wide array of therapeutic options currently available for 
treating RA, some patients continue to report unmet clinical needs, including ongoing 
pain, impaired physical/mental function and fatigue [39].  This observation can be seen in 
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the case of people who appear to be in clinical remission, as defined by a composite and 
to a large extent subjective DAS that in some countries represents the main determinant 
of use of the more effective, albeit more expensive treatments such as the biologic 
DMARDs.  This in part reflects discrepancies in the ‘definitions’ and the perception of 
‘remission’ or ‘treatment-success’ by physicians compared to patients, an increasingly 
acknowledged issue [40;41].  What has become clearly apparent over time though is that 
the phenotype and disease course of RA has largely evolved over the past few decades 
[42], with fewer patients having the destructive, deforming form of the disease that once 
represented ‘the norm’.  This is largely attributed to the discovery of better and more 
effective drugs over time enabling tighter disease control.  
However, even though the inflammatory burden of disease may be considerably 
improved, complete control of more subjective but highly important aspects of disease 
may continue to cause patient distress.  As a consequence, overall patient perception of 
well-being appears to have decreased with regard to outcome measures considered 
important by patients themselves, as opposed to the ones traditionally used to guide 
clinical decision making, including pain, fatigue, physical function and quality of life 
[43].  This, for many patients, provides an important incentive for taking a more active 
role in their health and reaching out to alternative ‘therapies’ and non-pharmacological 
treatments to manage their symptoms.   
 
5. What nutritional suggestions could be considered from the available evidence? 
Over the years, there have been strong influences around nutrition, mediated by social 
media, but not always robustly supported by scientific evidence.  The latter may reflect 
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the general lack of focus on nutrition in the literature on non-pharmacological 
interventions in inflammatory arthritis [44;45] where in contrast, interventions like 
exercise are recognized and reported.  The MD is a non-restrictive, well-balanced diet, 
including all food groups and providing all nutrients in an easy-to-follow manner.  
Similarly, n-3 PUFA supplements in moderate amounts seem to play a role in alleviating 
important symptoms that matter to patients. Box 1 summarizes nutritional suggestions 
that could be considered from the available evidence. 
 
Conclusions 
Dietary interventions such as the MD and fish oil supplementation are important in RA 
but we advocate that they are used in conjunction (and not as a replacement) with other 
non-dietary interventions including appropriate pharmacotherapy where indicated. There 
remains considerable uncertainty around the therapeutic benefits of specific dietary 
manipulations and food supplementation such as fish oils in the setting of RA. Although 
the evidence is generally reassuring, at least for some aspects of disease, larger RCTs of 
good methodological quality are warranted.  Addressing individual patient perceptions is 
important in guiding appropriate interventions, optimizing treatment outcomes, 
improving patient adherence and the sense of well-being.  This may be particularly 
relevant for people with RA who fail to achieve and sustain optimal treatment targets 
despite effective use of pharmacotherapy.  This work will be used to inform the research 
agenda for nutritional recommendations or points to consider for people with rheumatic 
and musculoskeletal diseases, RA included.  
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Box 1: Nutritional points to consider in RA regarding the MD and n-3 PUFA intake 
POINTS TO CONSIDER 
Mediterranean diet (MD) 
The MD* to be recommended to RA patients for its benefits on disease manifestations, 
arthritic pain and function.  
The MD to be recommended to RA patients for its benefits on comorbidities 
(cardio/neuro protection; anti-diabetic & anti-cancer and overall benefits on longevity). 
n-3 polyunsaturated fatty acid (PUFA) supplements and dietary n-3 PUFA 
Supplementation with n-3 PUFA in moderate amounts** for a period of at least 3 months 
to be recommended as an adjunct to treatment and in addition to the MD. 
Consumption of ‘fatty’ fish*** 2/week to be recommended 
Daily consumption of seeds^ and walnuts to be recommended. 
*Adherence to the MD can be achieved by consuming wholegrain foods daily, consuming 
beans and legumes ≥2 times/week, consuming ≥2 fruit/day, ≥3 vegetables/day, using 
extra virgin olive oil as main fat, limiting red meat intake to ≤1/week and consuming 
poultry instead, consuming fish 1-2 times/week, consuming ≤4 eggs/week, limiting sweets 
to special occasions and if alcohol is consumed, consume 1 glass of red wine with meals 
[6]. 
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** n-3 PUFA at doses ≥2.7 g/day based on meta-analysis [38] 
***Includes sardines, seabass, seabream, salmon, mackerel and trout, providing EPA 
and DHA.  
^Includes flaxseeds and chia seeds providing ALA. 
 
Table 1: Participants' characteristics and intervention details 
Study Sam
ple 
com
pleti
ng 
stud
y - 
inter
venti
on 
and 
contr
ol 
(% 
drop
out/
Ag
e 
in 
int
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up 
me
an 
+/- 
SD 
(ra
ng
e) 
Pr
op
ort
ion 
fe
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le 
in 
int
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) 
Intervention|Control diets Interventi
on length 
(months) 
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with
draw
al) 
McKe
llar et 
al, 
2007 
[15] 
130 
(0%) 
58 
(47
-
64)
** 
10
0 
MD|Healthy diet advice 6 
Sköld
stam 
et al, 
2003 
[16] 
51 
(9%) 
58 
(33
-
73) 
80 MD|WD 3 
Rema
ns et 
al, 
2004 
[20] 
55 
(17
%) 
60 
+/- 
11 
88 5g fat/d primarily: EPA (1400mg), DHA (211mg), DPA 
(40mg), ALA (16mg) GLA (500mg), LA (440mg) 
4 
Sköld
stam 
et al, 
1992 
43 
(7%) 
58 
(40 
-
82 10 FO capsule/d|10 VO capsule/d 1  
1 FO capsule = 1g FO  
1 VO capsule = 1g maize, olive and peppermint oils 
6 
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[21] 73) 
Clelan
d et 
al, 
1988 
[22] 
46 
(23
%) 
51 70 18g FO/d |18g OO/d 3 
Nielse
n et 
al, 
1992 
[24] 
6 
(11
%) 
61 
(33
-
78) 
No
t 
pro
vid
ed 
3.6g of n-3 PUFA/d | 3.6g/d fat combination, typical in a 
Danish diet 
3 
Rajaei 
et al, 
2015 
[25] 
49 
(18
%) 
42 
+/- 
7 
82 1.8 g EPA + 2.1 g DHA/starch capsules 3 
Geuse
ns et 
al, 
1994 
[26] 
60 
(30
%) 
LD
FO
: 
57
+/-
2;  
LD
FO
: 
76
* 
H
LDFO: 3 FO + 3 OO capsules (1.3 g of n-3); 
HDFO: 6 FO capsules (2.6 g of n-3);| 
control: 6 OO capsules;  
FO capsule = 1g FO each 
OO capsule = 1g OO each 
12 
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H
DF
O: 
59
+/-
2  
DF
O: 
79
* 
Krem
er et 
al, 
1990 
[27] 
49 
(23
%) 
LD
FO
: 
59 
(32
-
81)
;  
H
DF
O: 
58 
(30
-
80) 
67 LDFO: 27 mg/kg/d (9 mg EPA + 18 mg DHA/kg/d);  
HDFO: 54 mg/kg/d (18 mg EPA + 36 mg DHA /kg/d);|  
Control: 6.8g oleic acid/d  
6 
Krem 37 56 77 diet of PUFA: SFA ratio: 1.4:1 and1.8 g/d EPA |diet of 3 
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er et 
al, 
1985 
[28] 
(29
%) 
* PUFA:SFA: 1:4 and 10 placebo capsules of paraffin 
wax/d  
Adam 
et al, 
2003 
[29] 
62 
(9%) 
57
+/-
13 
93 1g FO/kg/d | 1g CO/kg/d 3 
Dawc
zynski 
et al, 
2009 
[30] 
39 
(13
%) 
58 
+/- 
11 
96 2.4g n−3 FA/d (from dairy products, where milk fat was 
partially replaced with fish + other oils)  
Control group had dairy products with comparable 
amount of non-n-3 FA fat.  
3 
interventi
on + 2 
washout 
+ 3 
control  
Krem
er et 
al, 
1995 
[31] 
49 
(26
%) 
until 
wee
k 18 
or 
22;  
58 55 130 mg/kg/d n-3 FA week on months 0-6.5 months, 
substituted with 100% corn oil on months 6.5-7.5|  
ontrol: 9 capsules/d corn oil for 7.5 months 
7.5 (+ 4.5 
on 
diclofena
c placebo 
+ corn 
oil) 
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29 
(56
%) 
until 
wee
k 26 
or 30 
Galarr
aga et 
al, 
2008 
[32] 
58 
(40
%) 
58 73 10 g FO (150 mg EPA, 70 mg DHA, 80 μg vitamin A, 
0.5 μg vitamin D, 20 IU vitamin E) | air-filled placebo 
capsule 
9 
Proud
man 
et al, 
2015 
[33] 
122 
(13
%) 
56 
+/- 
16 
71 5.5g/d FO | 0.4g/d FO 3.25 
Bahad
ori et 
al, 
2010 
[35] 
13 
(46
%) 
58 
+/- 
4 
91 0.2g/kg IV fish oil emulsion (100 ml contains 6.56 g of 
n-3: 2.82 g EPA, 3.09 g DHA, 0.20 g ALA, 0.45 g of 
DPA) followed by 0.05g/g  fish oil oral capsules | 0.9% 
OV saline infusion, followed by oral paraffin wax 
capsules  
14 days 
IV + 20 
weeks 
oral 
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Leeb 
et al, 
2006 
[36] 
30 
(12
%) 
60 
[± 
4.6
]^ 
83
^^ 
2 mL/kg IV fish oil emulsion (= 0.1-0.2 g fish oil/kg) 
(100 ml contains 6.56 g n-3 PUFA: 2.82 g EPA, 3.09 g 
DHA, 0.20 g ALA, 0.45 g of DPA) |no control group 
7 days 
Control group characteristics were not significantly different to intervention group 
characteristics, unless otherwise stated in text. 
% based on baseline data of intervention groups only (not taking into account dropouts or 
withdrawals); **median;  
^ showing median (95% CI) age for all participants completing study; ^^ % based on all 
participants completing study 
alpha-linolenic acid (ALA), corn oil (CO), docosahexaenoic acid (DHA), 
docosapentaenoic acid (DPA), eicosapentaenoic acid (EPA), fish oil (FO), gamma-
linolenic acid (GLA), linoleic acid (LA), low dose fish oil (LDFO), olive oil (OO), 
vegetable oil (VO) 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
Die
t 
Int
erv
enti
on 
Labo
rator
y 
Indic
es of 
Disea
se 
    
Clinic
al 
Indic
es of 
Disea
se 
              
Re
mis
sio
n 
Indi
ces 
     
  
E
S
R 
U
P 
C
R
P 
R
F 
B
l
e
e
d
i
n
g
 
t
i
m
e 
X
-
r
a
y
 
a
n
d
 
r
a
d
i
o
g
r
a
p
h
i
c 
p
a
r
a
m
e
t
e
r
s 
O
t
h
e
r 
l
a
b
o
r
a
t
o
r
y
 
m
e
a
s
u
r
e
s 
J
S
C 
J
T
C 
E
M
S 
G
S 
P
a
t
i
e
n
t
'
s
 
e
v
a
l
u
a
t
i
o
n
 
o
f 
p
a
i
n 
P
h
y
s
i
c
i
a
n
 
'
s
 
e
v
a
l
u
a
t
i
o
n
 
o
f 
p
a
i
n 
P
a
t
i
e
n
t
'
s
 
G
l
o
b
a
l 
E
v
a
l
u
a
t
i
o
n 
P
h
y
s
i
c
i
a
n
'
s
 
g
l
o
b
a
l 
e
v
a
l
u
a
t
i
o
n 
I
n
t
e
r
v
a
l 
t
o
 
o
n
s
e
t 
o
f 
f
a
t
i
g
u
e 
T
i
m
e
 
t
o
 
w
a
l
k 
R
i
t
c
h
i
e
'
s
 
i
n
d
e
x 
P
a
u
l
u
s
 
c
r
i
t
e
r
i
a 
H
A
Q 
A
C
R
2
0 
D
A
S
2
8 
V
A
S 
O
t
h
e
r 
A
C
R
 
r
e
m
i
s
s
i
o
n 
F
a
i
l
u
r
e
 
o
f 
t
r
i
p
l
e
 
D
M
A
R
D
 
t
h
e
r
a
p
y 
C
o
r
t
i
c
o
s
t
e
r
o
i
d
 
u
s
e 
N
S
A
I
D
 
u
s
e 
O
t
h
e
r 
  M
c
K
e
l
l
a
r
 
Me
dite
rra
nea
n 
diet / 
 
/ 
   
/
I
L
-
6 / / ↓ 
 
↓
^ 
 
↓ 
     
↓
^ 
 
/ 
         
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
e
t 
a
l
, 
2
0
0
7
 
[
1
5
] 
S
k
ö
l
d
s
t
a
m
 
e
t 
a
l
, 
2
0
0
3
 
[
1
6
] 
Me
dite
rra
nea
n 
diet / 
 
↓
* 
   
↓
 
t
h
r
o
m
b
o
c
y
t
e
 
c
o
u
n
t ↓ 
↓
* / / ↓ 
 
↓
* 
     
↓ 
 
↓ 
 
/S
OFI 
sco
re 
      R
e
m
a
n
s
 
e
t 
a
5g 
of 
fat, 
mai
nly 
ma
de 
up 
of 
EPA / 
 
/ 
    
/ / 
  
/ / 
        
/ / 
        
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
l
, 
2
0
0
4
 
[
2
0
] 
(14
00
mg)
, 
DH
A 
(21
1m
g), 
EPA 
(14
00
mg)
, 
DP
A 
(40
mg)
, 
ALA 
(16
mg) 
GL
A 
(50
0m
g), 
LA 
(44
0m
g) 
S
k
ö
l
d
s
t
a
m
 
e
t 
a
l
,  
1
9
Die
tar
y 
fish 
oil 
sup
ple
me
nta
tio
n ↑ 
 
/ 
   
↑ 
pla
tel
ets 
↓
* 
 
↑
* 
(lef
t 
ha
nd 
onl
y) 
↑
* / 
   
↓
* 
         
↓ 
   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
9
2
 
[
2
1
] 
C
l
e
l
a
n
d
 
e
t 
a
l
, 
1
9
8
8
 
[
2
2
] 
Dietary 
fish oil 
supplem
entation 
    
↓
L
T
B
4
, 
↓
5
-
H
E
T
E
, 
↓
L
T
B
4
+
L
T
B
5 
/
^ 
↓
^ 
/
^ 
↑
^ 
/
^ 
 
/ / 
 
/
^ 
     
/
^ 
        N
i
e
l
s
e
n
 
e
t 
a
l
, 
1
9
9
2
Die
tar
y 
fish 
oil 
sup
ple
me
nta
tio
n / 
 
↓
* 
    
/ ↓ 
↓
* / / 
                   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
[
2
4
] 
R
a
j
a
e
i 
e
t 
a
l
, 
2
0
1
5
 
[
2
5
] 
Die
tar
y 
fish 
oil 
sup
ple
me
nta
tio
n ↓ 
      
↓ ↓ ↓ 
 
↓ ↓ ↓ ↓ 
      
↓ 
         G
e
u
s
e
n
s
 
e
t 
a
l
, 
1
9
9
4
 
[
2
6
] 
Dietary 
fish oil 
supplem
entation 
- LDFO 
 
↑
* 
 
/ 
 
/ 
 
/ 
↑
* / / / 
   
↑
* 
         
/ / 
  
 
Die / 
  
/ 
 
/ 
 
/ 
 
/ ↑ / ↓ ↑ 
   
↑
         
↓ ↓ 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
tar
y 
fish 
oil 
sup
ple
me
nta
tio
n - 
HD
FO 
*  
(
"
N
S
A
I
D
 
o
r
 
D
M
A
R
D
"
) 
("NS
AID 
or 
DMA
RD") 
K
r
e
m
e
r
 
e
t 
a
l
, 
1
9
9
0
 
[
2
7
] 
Die
tar
y 
fish 
oil 
sup
ple
me
nta
tio
n - 
LDF
O / 
  
/ 
  
/IL-
1, 
/IL-
2 
↓
* 
↓
* 
↓
* / / / 
↓
* / 
               
 
Die
tar
y 
fish 
oil 
sup
ple
me / 
  
/ 
  
↓*
IL-
1, 
/IL-
2 
↓
* 
↓
* 
↓
* / 
↓
* / 
↓
* / 
               
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
nta
tio
n - 
HD
FO 
K
r
e
m
e
r
 
e
t 
a
l
, 
1
9
8
5
 
[
2
8
] 
Die
tar
y 
fish 
oil 
sup
ple
me
nta
tio
n 
/
* 
 
↓
* 
    
/
* 
/
* 
/
* 
/
* 
↓
* 
↓
* 
/
* 
/
* 
     
↑
* 
 
↑
* 
   
↓
^
* 
↓
* 
   A
d
a
m
 
e
t 
a
l
, 
2
0
0
3
 
[
2
9
] 
Die
tar
y 
fish 
oil 
sup
ple
me
nta
tio
n + 
WD 
/
* 
 
↓
* 
    
↓
* 
↓
* 
/
* 
/
* 
↓
↓ 
↓
↓ 
/
* 
/
* 
     
↑
↑ 
 
↑
↑ 
   
↓
* 
↓
* 
   
 
Die
tar
y 
/
* 
 
↓
* 
    
↓
* 
↓
* 
/
* 
/
* 
↓
↓ 
↓
↓ 
/
* 
/
* 
     
↑
↑ 
 
↑
↑ 
   
↓
* 
↓
* 
   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
fish 
oil 
sup
ple
me
nta
tio
n + 
AID 
D
a
w
c
z
y
n
s
k
i
, 
2
0
0
9
 
[
3
0
] 
Mil
k 
fat 
was 
par
tiall
y 
rep
lac
ed 
wit
h 
fish
, 
rap
ese
ed 
and 
Dra
coc
eph
alu
m 
ibe
ricu
m 
oil / 
 
↓
* 
    
/ / / 
           
/ 
         K
r
e
m
e
r
 
e
t 
a
l
, 
Dietary fish oil 
supplementation - 
change from 
baseline to week 
26/30 while on 
diclofenac palcebo 
↑* 
TN
F-α 
↓
* / / / / / 
↓
* / 
  
/ 
            
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
1
9
9
5
 
[
3
1
] 
 
Dietary fish oil 
supplementation - 
change from week 
18/22 to week 
26/30 
↓
*
 
I
L
-
1
β / 
↓
* / / / / 
↓
* / / 
  
/ 
            G
a
l
a
r
r
a
g
a
 
e
t 
a
l
, 
2
0
0
8
 
[
3
2
] 
Dietary 
fish oil 
supplem
entation 
     
/ / / / 
        
/ 
 
/ ↓ 
    
↓ 
   P
r
o
u
d
m
a
Dietary 
fish oil 
supplem
entation 
                 
/ 
   
/
E
U
L
A
R
 ↓ ↓ / / 
/
m
et
ho
tr
ex
at
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
n
 
e
t 
a
l
, 
2
0
1
5
 
[
3
3
] 
r
e
s
p
o
n
s
e 
e 
B
a
h
a
d
o
r
i 
e
t 
a
l
, 
2
0
1
0
 
[
3
5
] 
Intr
ave
nou
s 
fish 
oil 
infu
sio
n / / 
     
↓ ↓ 
                      L
e
e
b
 
e
t 
a
l
, 
Intr
ave
nou
s 
fish 
oil 
infu
sio
n / 
 
/ 
        
↓
* 
 
↓
* 
↓
* 
      
↓
* 
↓
* 
    
/ 
   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
Table 2: Results of reviewed studies, including laboratory and clinical parameters, 
as well as, parameters of remission. 
 
↓ significant decrease 
/ no significant result 
↓↓/↑↑ Result was significantly 
stronger vs placebo as well as 
vs other intervention group as 
well as vs 
* only within group i.e. 
compared to baseline 
^ mid-way assessment 
≠ EMS longer in the control group, no change in the experimental group  
5-Hydroxyeicosatetraenoic acid (5-HETE), American College of Rheumatology 20% 
improvement criteria (ACR20), Anti-inflammatory Diet (AID), alpha-linolenic acid 
2
0
0
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(ALA), corn oil (CO), C-reactive protein (CRP), Disease Activity Score-28 (DAS28), 
docosahexaenoic acid (DHA), disease-modifying antirheumatic drugs (DMARDs), 
docosapentaenoic acid (DPA), eicosapentaenoic acid (EPA), erythrocyte sedimentation rate 
(ESR), European League Against Rheumatism (EULAR), fish oil (FO), Health Assessment 
Questionnaire (HAQ), high dose fish oil (HDFO), low dose fish oil (LDFO), Leukotriene 
B4 (LTB4), Leukotriene B5 (LTB5), non-steroidal anti-inflammatory drugs (NSAID), 
olive oil (OO), Signals of Functional Impairment (SOFI), Tumour Necrosis Factor (TNF), 
Visual Analogue Scale (VAS), vegetable oil (VO), Western Diet (WD) 
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Highlights 
 Limited evidence that Mediterranean diet benefits pain, swollen and tender joints. 
 Fish oil supplements may improve symptoms and progression of 
pharmacotherapy. 
 Larger and methodologically-robust randomized controlled trials are necessary. 
 Firm conclusions on impact/effect size of nutritional interventions cannot be 
drawn.  
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